Jasper Therapeutics, Inc.

Jasper Therapeutics’ c-Kit inhibitor, briquilimab, demonstrated efficacy in a Phase II trial in patients with chronic spontaneous urticaria (CSU) that appears on par with rival Celldex’s barzolvolimab

Incyte Corporation sees potential in Escient Pharmaceuticals Inc. ’s MRGPR X2 and X4 antagonists to augment ongoing programs in its pipeline and to begin generating revenue at about the same time th

Novartis AG and Roche Holding AG ’s Xolair (omalizumab) has held a monopoly in chronic spontaneous urticaria for some years. Now, though, another agent might end Xolair’s solo reign: Novartis’s own

Black patients remain underrepresented in clinical trials, especially in studies of rare diseases, because they are not being recruited, Mary McGowan, CEO of the Foundation for Sarcoidosis Research (F